{"DataElement":{"publicId":"5783584","version":"1","preferredName":"Chemotherapy Mercaptopurine Methotrexate Agent Comprehension Of Taking Purpose Other Specify","preferredDefinition":"A textual reason not listed describing the understanding of the purpose of taking 6MP and Methotrexate.","longName":"5782837v1.0:2666713v2.0","context":"Alliance","contextVersion":"1","DataElementConcept":{"publicId":"5782837","version":"1","preferredName":"Chemotherapy Mercaptopurine Methotrexate Agent Comprehension Of Taking Purpose","preferredDefinition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases._A thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities.  Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5'-phosphate (6-thioGMP) and 6-thioinosine monophosphate (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis.  This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis. (NCI04)_An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect._What something is used for; reason or intention._An ability to understand the meaning or importance of something (or the knowledge acquired as a result)._As pertains to a medication: ingest, inhale, instill, or inject.","longName":"5782078v1.0:5782835v1.0","context":"Alliance","contextVersion":"1","ObjectClass":{"publicId":"5782078","version":"1","preferredName":"Chemotherapy Mercaptopurine Methotrexate Agent","preferredDefinition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.:A thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities.  Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5'-phosphate (6-thioGMP) and 6-thioinosine monophosphate (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis.  This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis. (NCI04):An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","longName":"C15632:C195:C642:C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Mercaptopurine","conceptCode":"C195","definition":"A thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities.  Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5'-phosphate (6-thioGMP) and 6-thioinosine monophosphate (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis.  This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Methotrexate","conceptCode":"C642","definition":"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E11966F-A200-17A2-E053-F662850A1F89","latestVersionIndicator":"Yes","beginDate":"2017-04-26","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-04-26","modifiedBy":"ONEDATA","dateModified":"2017-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5782835","version":"1","preferredName":"Comprehension Take Purpose","preferredDefinition":"An ability to understand the meaning or importance of something (or the knowledge acquired as a result).:As pertains to a medication: ingest, inhale, instill, or inject.:What something is used for; reason or intention.","longName":"C86022:C65105:C25634","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Comprehension","conceptCode":"C86022","definition":"An ability to understand the meaning or importance of something (or the knowledge acquired as a result).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Take","conceptCode":"C65105","definition":"As pertains to a medication: ingest, inhale, instill, or inject.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Purpose","conceptCode":"C25634","definition":"What something is used for; reason or intention.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E274EFA-3626-0742-E053-F662850A587A","latestVersionIndicator":"Yes","beginDate":"2017-04-27","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-04-27","modifiedBy":"ONEDATA","dateModified":"2017-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E274EFA-3637-0742-E053-F662850A587A","latestVersionIndicator":"Yes","beginDate":"2017-04-27","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-04-27","modifiedBy":"MORENOC","dateModified":"2017-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2666713","version":"2","preferredName":"Other Specify","preferredDefinition":"Different than the one(s) previously specified or mentioned._Be specific about something; define clearly.","longName":"OTH_SPEC","context":"NCI Standards","contextVersion":"1","type":"Non-enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2208051","version":"1","preferredName":"Other Specify","preferredDefinition":"Not otherwise specified.:Specify; be specific about something; define clearly.","longName":"C17649:C25685","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-3B5E-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCI CRF Standards","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"132D4785-528E-5337-E050-BB89AD433CA8","latestVersionIndicator":"Yes","beginDate":"2015-04-07","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2015-04-07","modifiedBy":"HARTLEYG","dateModified":"2018-06-06","changeDescription":"7/19/17 jk transferred context and added registration status, CSI per Round 5 finalization task. 4/28/15 released. jc  4/7/15 VD versioned per COG WG: inc to 100 char, remove min limit, chg concept domain to assessment result. jc 1/25/13 added ACRIN Old caBIG CSI.  3/21/12 - changed origin from IVI to ACRIN.  3/5/08 - released for UoWASH FES CRF.   7/23/07-created for ACRIN PET CDEs","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"specify","type":"Preferred Question Text","description":"specify","url":null,"context":"Alliance"}],"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E28D92F-14FE-26DC-E053-F662850A12D2","latestVersionIndicator":"Yes","beginDate":"2017-04-27","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-04-27","modifiedBy":"MORENOC","dateModified":"2017-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}